在贝赫特尿道炎中,免疫抑制疗法的药物保留时间
Donald Tran1, Sophie Rogers1, Lyndell L Lim1,2,3
1Centre for Eye Research Australia, Melbourne, Australia.
Ocular immunology and inflammation
|February 27, 2024
概括
生物疗法Adalimumab的药物保留时间比常规疾病修饰性抗风湿药 (DMARDs) 治疗贝赫特膜炎 (BU) 的时间相当或更好. 这表明Adalimumab是这种慢性炎症性眼病的有效治疗选择.
科学领域:
- 眼科医生 眼科 眼科
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 贝赫特病是一种慢性多系统性血管炎.
- 它经常与危及视力的脑膜炎有关.
- 对于 Behcet 脑膜炎 (BU) 的治疗方法,只有很少的比较研究.
研究的目的:
- 在BU患者中比较常规疾病修饰性抗风湿药物 (DMARD) 和生物DMARD的疗效和耐受性.
- 使用药物保留时间 (DRT) 作为治疗比较的替代措施.
主要方法:
- 对BU患者 (1985-2021) 的回顾性图表审查.
- 使用卡普兰-梅尔图表对DRT的分析.
- DRT定义为每个DMARD的第一个药物治疗周期的总时间.
主要成果:
- 中位数的DRT:阿达利穆马布 (52.0个月),甲酸 (27.4个月),甲甲酸 (24.0个月),环素 (14.0个月),阿扎西奥普林 (8.3个月).
- 副作用导致116人停止使用DMARD.
- 由于不耐受不良事件,患者从环素转换为阿达利木马布.
结论:
- 在BU患者中,Adalimumab的药物保留时间与传统的DMARD相似或更好.
- 这表明Adalimumab是一种可行的治疗选择,用于危及视力的贝赫特卵膜炎.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


